<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623673</url>
  </required_header>
  <id_info>
    <org_study_id>Retina CLINIC</org_study_id>
    <nct_id>NCT02623673</nct_id>
  </id_info>
  <brief_title>Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema</brief_title>
  <official_title>Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Clinic, Sao Paulo, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Clinic, Sao Paulo, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective cases series is a non-randomized, open-label, single-center investigation
      (Retina Clinic, São Paulo, Brazil) of patients diagnosed with macular edema secondary to
      diabetic retinopathy (DME) and retinal vein occlusions who underwent to simultaneous
      treatment with intravitreal injection of bevacizumab 1.25mg and implant of dexamethasone
      0.7mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective cases series is a non-randomized, open-label, single-center investigation
      (Retina Clinic, São Paulo, Brazil) approved by the Institutional Review Board of Hospital
      Oftalmológico de Sorocaba/SP, and adhered to the tenets of the Declaration of Helsinki. Were
      included patients older than 18 years, treated between April 2014 and July 2015, diagnosed
      with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who
      underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg
      (Avastin; Genentech, South San Francisco, CA) and intravitreal implant of dexamethasone 0.7mg
      (Ozurdex; Allergan, Inc, Irvine, CA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in BCVA</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>bevacizumab plus dexamethasone 0.7mg</arm_group_label>
    <description>simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.</intervention_name>
    <arm_group_label>bevacizumab plus dexamethasone 0.7mg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with macular edema
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  central macular thickness &gt; 300 µm on optical coherence tomography (OCT)

          -  macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions

        Exclusion Criteria:

          -  intravitreal anti-VEGF within 6 weeks

          -  treatment with laser or intravitreal corticosteroids within 3 months of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina Clinic / UNIFESP</name>
      <address>
        <city>São Paulo</city>
        <zip>06010-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>February 14, 2016</last_update_submitted>
  <last_update_submitted_qc>February 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Clinic, Sao Paulo, Brazil</investigator_affiliation>
    <investigator_full_name>Gabriel Costa de Andrade</investigator_full_name>
    <investigator_title>Gabriel Costa de Andrade</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

